Avadel Pharmaceuticals Announces Shareholder Meetings
Exciting developments are unfolding at Avadel Pharmaceuticals plc (NASDAQ: AVDL) as they prepare for an important Scheme Meeting and an Extraordinary General Meeting (EGM). Recently, the Avadel board reported that the Irish High Court has sanctioned the arrangement, a formal step in the ongoing acquisition endeavor led by Alkermes.
Details of the Upcoming Scheme Meeting
The Scheme Meeting has been officially scheduled for January 12, 2026, at 10:00 a.m. local time. This gathering is crucial as the shareholders of Avadel will gather to vote on the proposed scheme of arrangement, a structured method through which Alkermes aims to acquire the entire issued share capital of Avadel. This monumental move signifies a major shift in the landscape for both companies involved.
Extraordinary General Meeting Details
Following the Scheme Meeting, the EGM will commence on the same day at 10:15 a.m., or as soon as possible after the conclusion of the Scheme Meeting. The meetings will take place at the offices of Arthur Cox LLP in Dublin, providing shareholders with a formal setting to discuss and finalize crucial decisions impacting the company's future.
Proxy Statement and Key Information
In the lead-up to these significant meetings, Avadel will mail a proxy statement to their shareholders, likely around December 3, 2025. This document will serve as a comprehensive scheme circular that outlines the terms of the Proposed Transaction, the actions required from shareholders, and detailed voting instructions. Shareholders are encouraged to review this important material thoroughly to prepare for the meetings.
The Impact on Avadel Shareholders
As Avadel Pharmaceuticals transitions towards this potential acquisition by Alkermes, shareholders will need to closely consider their positions and the implications of the proposed transaction. The approval from shareholders will be pivotal, making this meeting a substantial opportunity for engagement and decision-making.
About Avadel Pharmaceuticals
Avadel Pharmaceuticals, trading under NASDAQ: AVDL, is an entity dedicated to transforming medicines for the betterment of patients' lives. The company focuses on innovative medication solutions that tackle challenges currently faced by patients. Their flagship product, LUMRYZ™, notably stands out as the first and only once-at-bedtime oxybate formulation approved by the U.S. FDA, delivering extended-release treatment solutions for narcolepsy-related symptoms.
Contacting Avadel Pharmaceuticals
For inquiries regarding the upcoming meetings or general investor relations, individuals can reach out to Avadel’s dedicated investor relations team. You can contact them via email at investors@avadel.com. Avadel encourages its shareholders to engage actively as the company navigates this transformative period.
Stay Informed on the Proposed Transaction
The upcoming meetings will primarily focus on the proposed scheme of arrangement with Alkermes. Shareholders are encouraged to keep up-to-date with any announcements regarding the meetings, especially following the mailing of the proxy statement. Comprehensive examinations of the materials provided will equip shareholders with necessary insights crucial for informed voting.
Frequently Asked Questions
What is the purpose of the upcoming Scheme Meeting?
The Scheme Meeting aims to gather Avadel shareholders to vote on a proposed arrangement for the acquisition of the company by Alkermes.
When will the EGM be conducted?
The EGM will take place on the same day as the Scheme Meeting, right after the conclusion of the earlier meeting.
How can shareholders prepare for the meetings?
Shareholders should review the upcoming proxy statement and familiarize themselves with the details regarding the proposed transaction.
What product does Avadel Pharmaceuticals focus on?
Avadel is known for its innovative product, LUMRYZ™, a treatment for narcolepsy symptoms.
How can we contact Avadel for investor inquiries?
Avadel’s investor relations can be reached at investors@avadel.com for any questions regarding the meetings or corporate matters.
